LILRB1 and neoplasm: In addition, the antibody enhanced ADCP by the anti-EGFR antibody cetuximab in vitro, thereby providing further evidence that LILRB1 blockade may enhance the therapeutic efficacy of tumor targeting antibodies by enhancing their ADCP function.